Related references
Note: Only part of the references are listed.Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis
Shanshan Wu et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Yue Fei et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study
Rebekka Faber et al.
Cardiovascular Diabetology (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Annachiara Uccellatore et al.
DIABETES THERAPY (2015)
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Annachiara Uccellatore et al.
DIABETES THERAPY (2015)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index
Michael Walsh et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
GRADE guidelines: 12. Preparing Summary of Findings tables-binary outcomes
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
Exenatide Reduces Final Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction and Short-Duration of Ischemia
Jacob Lonborg et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2012)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
John B. Buse et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
DIABETOLOGIA (2009)
Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses
Jesper Brok et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Share Paper
